Compare Amgen, Inc. (AMGN) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs JPMorgan Chase & Co — how do they compare? Amgen, Inc. trades at $356.4 (market cap $196.12B), while JPMorgan Chase & Co trades at $333.22 (market cap $901.58B). The key difference: JPMorgan Chase & Co is far larger — about 4.6× Amgen, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | JPM | |
|---|---|---|
Market Cap | $196.12B | $901.58B |
Sector | Health | Financials |
52-Week High | $388.16 | $339.22 |
52-Week Low | $271.18 | $282.84 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 1.78% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
JPMorgan Chase & Co. (JPM) trades at $337.80, up 0.4% on the day, with a bullish technical signal from moving averages and key resistance at $338. The stock shows strong fundamentals, including a 31.61% net income margin and 17.03% ROE, though Q4 2025 earnings missed expectations. Revenue grew to $181.85B in 2025, and analyst consensus is a Moderate Buy with a $360.38 price target. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 2026 earnings.
The outlook for JPM remains positive driven by earnings growth and sector resilience, but risks include geopolitical tensions, cybersecurity threats, and macroeconomic volatility. Institutional ownership trends show mixed activity, with some funds increasing stakes. The stock offers upside to the consensus target, though investors should monitor earnings results and economic indicators for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
